140P Preliminary Results from PROPEL: A Phase I/II Study of Bempegaldesleukin (BEMPEG: NKTR-214) Plus Pembrolizumab (PEMBRO) with or Without Chemotherapy in Patients with Metastatic NSCLC
Annals of oncology(2021)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined